|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
1 months to Dec 31, 2022
|
FY2021
9 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Operating Expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Impairment of goodwill | |||||
| Impairment of in-process research and development | |||||
| Total Operating Expenses | |||||
| Loss From Operations | |||||
| Other (Income) Expense: | |||||
| Interest expense | |||||
| Change in fair value of equity payable | |||||
| Pre-Tax Net Loss | |||||
| Income tax benefit (provision) | |||||
| Net Loss | |||||
| Deemed dividend to preferred stockholders | |||||
| Net Loss Attributable to Common Stockholders | |||||
| Net Loss Per Share | |||||
| Basic | |||||
| Diluted | |||||
| Total diluted | |||||
| Weighted Average Number of Common Shares Outstanding | |||||
| Basic | |||||
| Total basic | |||||
| Diluted | |||||
Loading...